Orexin loss in Huntington's disease

被引:204
作者
Petersén, Å
Gil, J
Björkqvist, M
Tanila, H
Araújo, IM
Smith, R
Popovic, N
Wierup, N
Norlén, P
Li, JY
Roos, RAC
Sundler, F
Mulder, H
Brundin, P
机构
[1] Dept Physiol Sci, Sect Neuronal Survival, S-22184 Lund, Sweden
[2] LUMC, Dept Neurol, Leiden, Netherlands
[3] Dept Cell & Mol Biol, Lund, Sweden
[4] Univ Kuopio, Kuopio Univ Hosp, Dept Neurol, Dept Neurol & Neurosci, FIN-70211 Kuopio, Finland
[5] Ctr Neurosci & Cell Biol, Dept Zool, Coimbra, Portugal
[6] Dept Physiol Sci, Sect Neuroendocrine Cell Biol, Lund, Sweden
[7] Univ Lund Hosp, Inst Lab Med, Dept Expt & Clin Pharmacol, S-22185 Lund, Sweden
关键词
D O I
10.1093/hmg/ddi004
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Huntington's disease (HD) is a devastating neurodegenerative disorder caused by an expanded CAG repeat in the gene encoding huntingtin, a protein of unknown function. Mutant huntingtin forms intracellular aggregates and is associated with neuronal death in select brain regions. The most studied mouse model (R6/2) of HD replicates many features of the disease, but has been reported to exhibit only very little neuronal death. We describe for the first time a dramatic atrophy and loss of orexin neurons in the lateral hypothalamus of R6/2 mice. Importantly, we also found a significant atrophy and loss of orexin neurons in Huntington patients. Like animal models and patients with impaired orexin function, the R6/2 mice were narcoleptic. Both the number of orexin neurons in the lateral hypothalamus and the levels of orexin in the cerebrospinal fluid were reduced by 72% in end-stage R6/2 mice compared with wild-type littermates, suggesting that orexin could be used as a biomarker reflecting neurodegeneration. Our results show that the loss of orexin is a novel and potentially very important pathology in HD.
引用
收藏
页码:39 / 47
页数:9
相关论文
共 42 条
[1]   Energetics in the pathogenesis of neurodegenerative diseases [J].
Beal, MF .
TRENDS IN NEUROSCIENCES, 2000, 23 (07) :298-304
[2]   Experimental therapeutics in transgenic mouse models of Huntington's disease [J].
Beal, MF ;
Ferrante, RJ .
NATURE REVIEWS NEUROSCIENCE, 2004, 5 (05) :373-384
[3]   Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation [J].
Behrens, P. F. ;
Franz, P. ;
Woodman, B. ;
Lindenberg, K. S. ;
Landwehrmeyer, G. B. .
BRAIN, 2002, 125 :1908-1922
[4]   Expression of a poly-glutamine-ataxin-3 transgene in orexin neurons induces narcolepsy-cataplexy in the rat [J].
Beuckmann, CT ;
Sinton, CM ;
Williams, SC ;
Richardson, JA ;
Hammer, RE ;
Sakurai, T ;
Yanagisawa, M .
JOURNAL OF NEUROSCIENCE, 2004, 24 (18) :4469-4477
[5]   Loss of normal huntingtin function: new developments in Huntington's disease research [J].
Cattaneo, E ;
Rigamonti, D ;
Goffredo, D ;
Zuccato, C ;
Squitieri, F ;
Sipione, S .
TRENDS IN NEUROSCIENCES, 2001, 24 (03) :182-188
[6]  
Cepeda C, 2003, J NEUROSCI, V23, P961
[7]   Narcolepsy in orexin knockout mice:: Molecular genetics of sleep regulation [J].
Chemelli, RM ;
Willie, JT ;
Sinton, CM ;
Elmquist, JK ;
Scammell, T ;
Lee, C ;
Richardson, JA ;
Williams, SC ;
Xiong, YM ;
Kisanuki, Y ;
Fitch, TE ;
Nakazato, M ;
Hammer, RE ;
Saper, CB ;
Yanagisawa, M .
CELL, 1999, 98 (04) :437-451
[8]   The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activity [J].
De Lecea, L ;
Kilduff, TS ;
Peyron, C ;
Gao, XB ;
Foye, PE ;
Danielson, PE ;
Fukuhara, C ;
Battenberg, ELF ;
Gautvik, VT ;
Bartlett, FS ;
Frankel, WN ;
van den Pol, AN ;
Bloom, FE ;
Gautvik, KM ;
Sutcliffe, JG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (01) :322-327
[9]   Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain [J].
DiFiglia, M ;
Sapp, E ;
Chase, KO ;
Davies, SW ;
Bates, GP ;
Vonsattel, JP ;
Aronin, N .
SCIENCE, 1997, 277 (5334) :1990-1993
[10]  
Hansen Stig, 2001, HeartDrug, V1, P14, DOI 10.1159/000022705